Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer

1003Background: Utidelone, a genetically engineered epothilone analog, showed excellent efficacy in phase II and III trials in terms of PFS as a primary end point and ORR as a secondary end point. ...